OncoMatch/Clinical Trials/NCT06290687
Partial Cystectomy & Extended Pelvic Lymph Node Dissection With SOC Perioperative Systemic Therapy
Is NCT06290687 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Neoadjuvant Chemotherapy and Adjuvant systemic therapy for malignant neoplasm of bladder.
Treatment: Neoadjuvant Chemotherapy · Adjuvant systemic therapy — The goal of this clinical trial is to determine if a partial cystectomy with extended pelvic lymph node removal will be effective at treating Muscle-Invasive Bladder Cancer instead of a complete cystectomy with extended pelvic lymph node removal. This clinical trial aims to determine the safety and oncologic efficacy of the intervention, and to examine patient-reported quality of life outcomes in participants. Participants will receive the standard pre-surgery treatment for approximately 4 to 6 weeks. After the pre-surgery treatment is completed, participants will undergo a partial cystectomy with extended pelvic lymph node dissection. After surgery, participants will receive adjuvant systemic therapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Urothelial Carcinoma
Disease stage
Excluded: Stage M+, CT4+
clinical stage T2-3N0M0; Presence of clinical N+ or M+ disease [excluded]; Presence of cT4+ disease [excluded]
Performance status
KARNOFSKY OR ECOG 0–1
Karnofsky Performance Status ≥70 or Eastern Cooperative Oncology Group (ECOG) performance status Grade 0 or 1
Demographics
Prior therapy
Lab requirements
Blood counts
Absolute neutrophil count (ANC) ≥ 1,500/mm3; Platelet count ≥ 80,000/mm3; Hemoglobin ≥ 9.0 g/dL
Liver function
Total bilirubin within normal limits; AST (SGOT) ≤ 2.5 X institutional upper limit of normal; ALT (SGPT) ≤ 2.5 X institutional upper limit of normal
Subjects must have normal organ and marrow function as defined below: Total bilirubin within normal limits; AST (SGOT) ≤ 2.5 X institutional upper limit of normal; ALT (SGPT) ≤ 2.5 X institutional upper limit of normal; Bone marrow: Absolute neutrophil count (ANC) ≥ 1,500/mm3; Platelet count ≥ 80,000/mm3, Hemoglobin ≥ 9.0 g/dL
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Glickman Urological and Kidney Institute, Cleveland Clinic, Case Comprehensive Cancer Center · Cleveland, Ohio
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06290687 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages